title: [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
abstract: In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications are described.
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
authors.forename: L L
authors.initials: LL
authors.lastname: Kamynina
authors.forename: Z G
authors.initials: ZG
authors.lastname: Akhmedova
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D002316:Cardiotonic Agents; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1